BeiGene secures FDA approval for stomach cancer drug | MSN
Excerpt from the MSN: “BeiGene (BGNE) said Friday the US Food and Drug Administration approved Tevimbra, its drug to treat a form of stomach cancer, in combination with chemotherapy.
Tevimbra, or tislelizumab-jsgr, is approved as a first-line treatment for adults suffering from a certain type of unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, which occurs where the esophagus connects with the stomach, according to the oncology company. The drug is to be used in combination with platinum and fluoropyrimidine-based chemotherapy.” Read more.
FDA approval of injectable Opdivo: Bristol Myers Squibb fights off patent cliff concerns | Yahoo Finance
Excerpt from Yahoo Finance: “Opdivo, an injectable variation of Bristol Myers Squibb’s (NYSE:BMY) cancer immunotherapy medication, has been approved by the U.S. Food and Drug Administration. Announced Friday, the approval is expected to provide patients with a more practical choice and strengthen the market position of the medication as it gets near a patent cliff.” Read more.
Inogen gets FDA Clearance for airway clearance device | MarketWatch
Excerpt from MarketWatch: “Inogen said regulators have cleared its SIMEOX 200 Airway Clearance Device to be used by U.S. patients with chronic respiratory diseases.
The medical technology company said Monday that the Food and Drug Administration’s 510(k) clearance paves the way for a limited launch of SIMEOX 200 in targeted sites next year.” Read more.
Sorry, the comment form is closed at this time.